Caitlyn Vlasschaert

Dr. Caitlyn Vlasschaert


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
AMAmy J.M. McNaughton
Amy J.M. McNaughton
MCMichael Chong
Michael Chong
ECElina K. Cook
Elina K. Cook
WHWilma Hopman
Wilma Hopman
Matthew B. LanktreeMatthew B. Lanktree
Matthew B. Lanktree
Background: Clonal hematopoiesis of indeterminate potential (CHIP) is an inflammatory premalignant disorder resulting from acquired genetic mutations in hematopoietic stem cells. This condition is common in aging populations and associated with cardiovascular morbidity and overall mortality, but its role in CKD is unknown. Methods: We performed targeted sequencing to detect CHIP mutations in two independent cohorts of 87 and 85 adults with an eGFR<60 ml/min per 1.73m2. We also assessed kidney function, hematologic, and mineral bone disease parameters cross-sectionally at baseline, and collected creatinine measurements over the following 5-year period. Results: At baseline, CHIP was detected in 18 of 87 (21%) and 25 of 85 (29%) cohort participants. Participants with CHIP were at higher risk of kidney failure, as predicted by the Kidney Failure Risk Equation (KFRE), compared with those without CHIP. Individuals with CHIP manifested a 2.2-fold increased risk of a 50% decline in eGFR or ESKD over 5 years of follow-up (hazard ratio 2.2; 95% confidence interval, 1.2 to 3.8) in a Cox proportional hazard model adjusted for age, sex, and baseline eGFR. The addition of CHIP to 2-year and 5-year calibrated KFRE risk models improved ESKD predictions. Those with CHIP also had lower hemoglobin, higher ferritin, and higher red blood cell mean corpuscular volume versus those without CHIP. Conclusions: In this exploratory analysis of individuals with preexisting CKD, CHIP was associated with higher baseline KFRE scores, greater progression of CKD, and anemia. Further research is needed to define the nature of the relationship between CHIP and kidney disease progression.

15 September 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ZYZhi Yu
Zhi Yu
TFTrevor P. Fidler
Trevor P. Fidler
YRYunfeng Ruan
Yunfeng Ruan
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
TNTetsushi Nakao
Tetsushi Nakao
PNPradeep Natarajan
Pradeep Natarajan
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an increased risk of cardiovascular diseases (CVDs), putatively via inflammasome activation. We pursued an inflammatory gene modifier scan for CHIP-associated CVD risk among 424,651 UK Biobank participants. We identified CHIP using whole-exome sequencing data of blood DNA and modeled as a composite, considering all driver genes together, as well as separately for common drivers (DNMT3A, TET2, ASXL1, and JAK2). We developed predicted gene expression scores for 26 inflammasome-related genes and assessed how they modify CHIP-associated CVD risk. We identified IL1RAP as a potential key molecule for CHIP-associated CVD risk across genes and increased AIM2 gene expression leading to heightened JAK2- and ASXL1-associated CVD risk. We show that CRISPR-induced Asxl1-mutated murine macrophages had a particularly heightened inflammatory response to AIM2 agonism, associated with an increased DNA damage response, as well as increased IL-10 secretion, mirroring a CVD-protective effect of IL10 expression in ASXL1 CHIP. Our study supports the role of inflammasomes in CHIP-associated CVD and provides evidence to support gene-specific strategies to address CHIP-associated CVD risk.

23 September 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
CGChloe J. Goss
Chloe J. Goss
NPNathan G. Pilkey
Nathan G. Pilkey
SMSandra McKeown
Sandra McKeown
RHRachel Holden
Rachel Holden
Matrix gla protein (MGP) is an important vitamin K-dependent inhibitor of vascular calcification. High levels of uncarboxylated, dephosphorylated MGP have been associated with vascular calcification and are responsive to vitamin K treatment. In this systematic review, we summarize the available evidence examining whether vitamin K supplementation improves surrogate measures of cardiovascular disease including artery and valve calcification, atherosclerosis and artery stiffening. Data from controlled trials of adults were obtained by searching Ovid MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and the Web of Science Core Collection. We identified nine randomized controlled trials for review, including trials of vitamin K1 or vitamin K2 supplementation, that assessed a surrogate measure of cardiovascular disease including arterial calcification, atherosclerosis or arterial stiffening. For each trial, the risk of bias was assessed applying Cochrane Collaboration methodology. The findings indicate that vitamin K does not consistently prevent progression of calcification, atherosclerosis or arterial stiffness. There may be some benefit in people with calcification at study entry. Studies were heterogenous, with relatively short follow-up and outcome measures were varied. While vitamin K supplementation clearly improves the carboxylation of dephosphoylated MGP, its role in mitigating vascular calcification is uncertain, based on current evidence.

11 July 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
JHJonathan Brett Heimlich
Jonathan Brett Heimlich
PBPawan Bhat
Pawan Bhat
APAlyssa C. Parker
Alyssa C. Parker
MJMatthew T. Jenkins
Matthew T. Jenkins
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
PFP. Brent Ferrell
P. Brent Ferrell
Clonal hematopoiesis (CH) is an age-associated phenomenon that increases the risk of hematologic malignancy and cardiovascular disease. CH is thought to enhance disease risk through inflammation in the peripheral blood.1 Here, we profile peripheral blood gene expression in 66 968 single cells from a cohort of 17 patients with CH and 7 controls. Using a novel mitochondrial DNA barcoding approach, we were able to identify and separately compare mutant Tet methylcytosine dioxygenase 2 (TET2) and DNA methyltransferase 3A (DNMT3A) cells with nonmutant counterparts. We discovered the vast majority of mutated cells were in the myeloid compartment. Additionally, patients harboring DNMT3A and TET2 CH mutations possessed a proinflammatory profile in CD14+ monocytes through previously unrecognized pathways such as galectin and macrophage inhibitory factor. We also found that T cells from patients with CH, although mostly unmutated, had decreased expression of GTPase of the immunity associated protein genes, which are critical to T-cell development, suggesting that CH impairs T-cell function.

4 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CQCandice Quin
Candice Quin
EDErica N. DeJong
Erica N. DeJong
ECElina K. Cook
Elina K. Cook
YLYi Zhen Luo
Yi Zhen Luo
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
DBDawn M. E. Bowdish
Dawn M. E. Bowdish
Individuals with clonal hematopoiesis of indeterminate potential (CHIP) are at increased risk of aging related health conditions and all-cause mortality, but whether CHIP affects risk of infection is much less clear. Using UK Biobank data, we revealed a positive association between CHIP and incident pneumonia in 438,421 individuals. We show that inflammation enhanced pneumonia risk, as CHIP carriers with a hypomorphic IL6 receptor polymorphism were protected. To better characterize the pathways of susceptibility, we challenged hematopoietic Tet Methylcytosine Dioxygenase 2– knockout ( Tet2 –/– ) and floxed control mice ( Tet2 fl/fl ) with Streptococcus pneumoniae . As with human CHIP carriers, Tet2 –/– mice had hematopoietic abnormalities resulting in the expansion of inflammatory monocytes and neutrophils in peripheral blood. Yet, these cells were insufficient in defending against S . pneumoniae and resulted in increased pathology, impaired bacterial clearance, and higher mortality in Tet2 –/– mice. We delineated the transcriptional landscape of Tet2 –/– neutrophils and found that, while inflammation-related pathways were upregulated in Tet2 –/– neutrophils, migration and motility pathways were compromised. Using live-imaging techniques, we demonstrated impairments in motility, pathogen uptake, and neutrophil extracellular trap (NET) formation by Tet2 –/– neutrophils. Collectively, we show that CHIP is a risk factor for bacterial pneumonia related to innate immune impairments.

9 April 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
YPYang Pan
Yang Pan
JCJianchun Chen
Jianchun Chen
EAElvis Akwo
Elvis Akwo
VRVarun Rao
Varun Rao
TKTanika Kelly
Tanika Kelly
Key Points: Non- DNMT3A clonal hematopoiesis of indeterminate potential was associated with CKD progression in a meta-analysis of 5654 individuals with CKD. In an adenine-induced CKD mouse model, Tet2 -clonal hematopoiesis of indeterminate potential was linked to lower GFR, increased kidney inflammation, tubular injury, and fibrosis. Background: Clonal hematopoiesis of indeterminate potential (CHIP) is a common inflammatory condition of aging that causes myriad end-organ damage. CHIP has been associated with incident AKI and kidney function decline in the general population, particularly mutations in CHIP genes other than DNMT3A (termed non- DNMT3A CHIP). Previous studies of CHIP in individuals with CKD had limited sample sizes and conflicting findings. Methods: We examined CHIP and CKD progression in four CKD cohorts ( N =5654): the Chronic Renal Insufficiency Cohort, the African American Study of Kidney Disease, individuals with CKD from the BioVU biorepository, and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events. Primary outcomes were incident CKD progression (50% eGFR decline or kidney failure) and eGFR slope over time. In addition, kidney function and pathology were assessed in a Tet2 -CHIP mouse model of CKD induced by dietary adenine. Results: Across all cohorts, the average age was 66±11 years, with an average baseline eGFR of 43±15 ml/min per 1.73 m 2 , and 24% had CHIP. After meta-analysis, non- DNMT3A CHIP was associated with a 64% higher relative risk of incident CKD progression (hazard ratio, 1.64; 95% confidence interval, 1.00 to 2.68), with the strongest effect observed in individuals with baseline eGFR 30–60 ml/min per 1.73 m 2 (hazard ratio, 1.85; 95% confidence interval, 1.18 to 2.90). Non- DNMT3A CHIP carriers also exhibited a faster eGFR decline ( β , −0.62±0.28 ml/min per 1.73 m 2 per year; P = 0.03). In a dietary adenine mouse model of CKD, Tet2 -CHIP was associated with lower GFR as well as greater kidney inflammation, tubular injury, and tubulointerstitial fibrosis. Conclusions: Non- DNMT3A CHIP was associated with CKD progression among individuals with CKD. Furthermore, Tet2 -CHIP mouse models support a causal role in kidney injury.